Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by U. Hasler-Strub
A Randomized Phase II Study Evaluating Different Maintenance Schedules of Nab-Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer: Final Results of the IBCSG 42-12/Big 2-12 SNAP Trial
Annals of Oncology
Medicine
Oncology
Hematology
Related publications
A Randomized Phase 2 Trial Comparing 3-Hour Versus 96-Hour Infusion Schedules of Paclitaxel for the Treatment of Metastatic Breast Cancer
Cancer
Cancer Research
Oncology
A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line Treatment for Patients With Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer
Oncologist
Cancer Research
Medicine
Oncology
Caveolin-1 Expression Predicts Efficacy of Weekly Nab-Paclitaxel Plus Gemcitabine for Metastatic Breast Cancer in the Phase II Clinical Trial
BMC Cancer
Cancer Research
Oncology
Genetics
Role of Nab-Paclitaxel in Metastatic Breast Cancer: A Meta-Analysis of Randomized Clinical Trials
Oncotarget
Oncology
Phase II Trial of Nab-Paclitaxel in the Treatment of Recurrent or Persistent Advanced Cervix Cancer: A Gynecologic Oncology Group Study
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
A Randomized, Controlled Phase II Trial of Neoadjuvant Ado-Trastuzumab Emtansine, Lapatinib, and Nab-Paclitaxel Versus Trastuzumab, Pertuzumab, and Paclitaxel in HER2-positive Breast Cancer (TEAL Study)
Breast Cancer Research
Cancer Research
Oncology
Multicenter Phase II Study With Weekly Bendamustine and Paclitaxel as First- Or Later-Line Therapy in Patients With Metastatic Breast Cancer: RiTa II Trial
Breast Care
Surgery
Oncology
Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer
Anti-Cancer Drugs
Cancer Research
Oncology
Pharmacology
Nab-Paclitaxel as Second-Line Treatment in Advanced Gastric Cancer: A Multicenter Phase II Study of the Hellenic Oncology Research Group
Annals of Gastroenterology
